+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen



The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen



European Journal of Gynaecological Oncology 35(5): 492-498



To review the evidence concerning the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in preventing endometrial pathology in women treated with tamoxifen. Randomized controlled trials (RCTs) of women with breast cancer on tamoxifen that compared endometrial surveillance or placebo alone vs. the LNG-IUS were reviewed. The eligible trials were identified from the following electronic databases: Cochrane CENTRAL, Medline, and EMBASE. The authors extracted data on all reported outcomes and conducted meta-analyses on the endometrial polyps, endometrial hyperplasia, proliferative endometrium, and endometrium thickness. According to the subgroup analysis, a significant reduction of endometrial polyps was obtained (OR = 0.22, 95% CI 0.13-0.37, p < 0.00001). The use of LNG-IUS reduced the incidence of endometrial hyperplasia (OR = 0.13, 95% CI 0.03-0.58, p = 0.007). Increased abnormal vaginal bleeding for LNG-IUS users may be an adverse aspect of LNG-IUS. This meta-analysis confirms that endometrial hyperplasia is also reduced as well as endometrial polyp formation reduced after long-term follow-up.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 056479880

Download citation: RISBibTeXText

PMID: 25423691


Related references

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2016(12): Cd007245, 2016

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2010(4): Cd007245, 2010

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen: A cochrane review summary. Maturitas 89: 1-2, 2016

Prophylactic Use of Levonorgestrel-Releasing Intrauterine System in Women With Breast Cancer Treated With Tamoxifen. Obstetrical & Gynecological Survey 68(8): 568-570, 2013

Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 11(3): 252-257, 2008

Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial. Lancet (North American Edition) 356(9243): 1711-1717, 18 November, 2000

Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstetrics and Gynecology 121(5): 943-950, 2013

Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. International Journal of Clinical and Experimental Pathology 7(10): 6419-6429, 2015

Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report. Journal of Minimally Invasive Gynecology 16(5): 630-633, 2009

Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecologic Oncology 114(3): 452-456, 2009

Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast Cancer Research and Treatment 167(1): 257-262, 2017

Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecologic Oncology 149(1): 127-132, 2018

The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric 18(4): 470-482, 2016

The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. Journal of Gynecologic Oncology 21(2): 102-105, 2010

Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: balance of breast risks and endometrial benefits--systematic review of literature. Reproductive Sciences 21(4): 423-431, 2015